NDAORALTABLET, FOR SUSPENSION
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PREZCOBIX (darunavir ethanolate and cobicistat) by Johnson & Johnson is cytochrome p450 3a inhibitors [moa]. Approved for cytochrome p450 3a inhibitor [epc]. First approved in 2026.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREZCOBIX is a fixed-dose combination of darunavir ethanolate (a protease inhibitor) and cobicistat (a cytochrome P450 3A inhibitor) approved as an oral tablet for suspension. It functions as a boosting agent that enhances the pharmacokinetics of protease inhibitors by inhibiting cytochrome P450 3A metabolism. This combination is used in HIV treatment regimens to improve drug efficacy and reduce pill burden.
Launch
New 2026 launch presents early-stage commercial opportunity with moderate competitive pressure (30 baseline); limited linked roles suggest emerging team build phase.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREZCOBIX launch in February 2026 represents a ground-floor commercial opportunity within J&J's established HIV franchise, though limited current job openings (0 linked roles) suggest hiring will accelerate post-approval. Career growth will depend on driving market adoption against entrenched competition and newer mechanism alternatives.
Brand Manager
Worked on PREZCOBIX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.